Search Result

Results for "

COVID-19

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) ADC Cytotoxin (4) Adenosine Receptor (1) Akt (2) Angiotensin-converting Enzyme (ACE) (4) Antibiotic (15) Apoptosis (10) Autophagy (29) Bacterial (14) Bcl-2 Family (3) Biochemical Assay Reagents (1) Btk (1) c-Fms (2) Calcium Channel (1) Cannabinoid Receptor (2) Caspase (1) Cathepsin (1) CD6 (1) CD73 (1) CDK (6) Ceramidase (1) Complement System (13) Dengue virus (1) DNA/RNA Synthesis (16) Dopamine Receptor (3) Drug Metabolite (3) Elastase (4) Endogenous Metabolite (11) ERK (1) FAAH (3) Factor Xa (1) Fatty Acid Synthase (FASN) (3) Filovirus (2) Flavivirus (1) Fluorescent Dye (1) Fungal (2) Glucocorticoid Receptor (14) Glutathione Peroxidase (1) GPR68 (1) HBV (1) HCV (4) HIF/HIF Prolyl-Hydroxylase (2) HIV (9) HSP (1) HSV (6) IKK (1) Influenza Virus (6) Interleukin Related (7) Isotope-Labeled Compounds (16) JAK (1) JNK (1) Keap1-Nrf2 (2) Leukotriene Receptor (4) Liposome (4) Mitophagy (9) Neprilysin (3) NF-κB (2) Nucleoside Antimetabolite/Analog (8) Orthopoxvirus (4) p38 MAPK (1) Parasite (10) Phosphatase (1) PROTACs (1) Proteasome (1) Ras (1) Reactive Oxygen Species (4) RSV (2) SARS-CoV (168) Sigma Receptor (2) Sirtuin (4) STAT (1) Thrombin (1) Toll-like Receptor (TLR) (13) Virus Protease (13)
By Research Areas:	Cancer (69) Cardiovascular Disease (7) Endocrinology (12) Infection (173) Inflammation/Immunology (72) Metabolic Disease (14) Neurological Disease (16)

By Targets:

5-HT Receptor (3)

ADC Cytotoxin (4)

Adenosine Receptor (1)

Akt (2)

Angiotensin-converting Enzyme (ACE) (4)

Antibiotic (15)

Apoptosis (10)

Autophagy (29)

Bacterial (14)

Bcl-2 Family (3)

Biochemical Assay Reagents (1)

Btk (1)

c-Fms (2)

Calcium Channel (1)

Cannabinoid Receptor (2)

Caspase (1)

Cathepsin (1)

CD6 (1)

CD73 (1)

CDK (6)

Ceramidase (1)

Complement System (13)

Dengue virus (1)

DNA/RNA Synthesis (16)

Dopamine Receptor (3)

Drug Metabolite (3)

Elastase (4)

Endogenous Metabolite (11)

ERK (1)

FAAH (3)

Factor Xa (1)

Fatty Acid Synthase (FASN) (3)

Filovirus (2)

Flavivirus (1)

Fluorescent Dye (1)

Fungal (2)

Glucocorticoid Receptor (14)

Glutathione Peroxidase (1)

GPR68 (1)

HBV (1)

HCV (4)

HIF/HIF Prolyl-Hydroxylase (2)

HIV (9)

HSP (1)

HSV (6)

IKK (1)

Influenza Virus (6)

Interleukin Related (7)

Isotope-Labeled Compounds (16)

JAK (1)

JNK (1)

Keap1-Nrf2 (2)

Leukotriene Receptor (4)

Liposome (4)

Mitophagy (9)

Neprilysin (3)

NF-κB (2)

Nucleoside Antimetabolite/Analog (8)

Orthopoxvirus (4)

p38 MAPK (1)

Parasite (10)

Phosphatase (1)

PROTACs (1)

Proteasome (1)

Ras (1)

Reactive Oxygen Species (4)

RSV (2)

SARS-CoV (168)

Sigma Receptor (2)

Sirtuin (4)

STAT (1)

Thrombin (1)

Toll-like Receptor (TLR) (13)

Virus Protease (13)

By Research Areas:

Cancer (69)

Cardiovascular Disease (7)

Endocrinology (12)

Infection (173)

Inflammation/Immunology (72)

Metabolic Disease (14)

Neurological Disease (16)

225

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Bebtelovimab LY-3853113; LY-COV1404	SARS-CoV	Infection
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .

Quisovalimab AVTX-002; AEVI 002; SAR 252067	SARS-CoV	Cardiovascular Disease
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .

COVID-19 Spike Protein mRNA-LNP	SARS-CoV Liposome	Infection
COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing COVID-19 Spike Protein, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 Spike Protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 Spike Protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .

COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP)	SARS-CoV	Infection
COVID-19 Spike Protein mRNA will express COVID-19 spike protein, and suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 spike protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 spike protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 spike protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .

Guanosine triphosphate GTP	SARS-CoV Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Endogenous Metabolite	Infection Cancer
Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19 .

Plonmarlimab TJ003234; TJM2	c-Fms SARS-CoV	Infection Inflammation/Immunology
Plonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19 .

SARS-CoV-2 Mpro-IN-3	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-3 is a potent M ^pro inhibitor with an IC₅₀ value of ﹥5 μM. SARS-CoV-2 Mpro-IN-3 can be used in research of COVID-19 .

Ruzotolimod RO7020531; RG7854	Toll-like Receptor (TLR)	Infection
Ruzotolimod is the agonist of TLR7. Ruzotolimod has the potential for the research of HBV, COVID-19 or SARS-CoV-2 infection (extracted from patent WO2021130195A1) .

SARS-CoV-2-IN-35	SARS-CoV	Infection
SARS-CoV-2-IN-35 is a potent and orally active SARS-CoV-2 M ^pro inhibitor with a K_i value of 12.1 nM. SARS-CoV-2-IN-35 can be used in research of COVID-19 .

GS-704277 2 Publications Verification	Drug Metabolite	Infection
GS-704277 is an alanine metabolite of Remdesivir. Remdesivir, a nucleoside analogue with effective antiviral activity, is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

Masavibart ZRC3308-A7	SARS-CoV	Infection
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

Nepuvibart ZRC3308-B10	SARS-CoV	Infection
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

WDB002	Others	Infection Inflammation/Immunology
WDB002, a natural product, is a member of the FK506/rapamycin family. WDB002 can target CEP250. WDB002 can be used for the research of COVID-19 .

Dabcyl-KTSAVLQSGFRKM-Glu(Edans)-NH2	Virus Protease	Others
Dabcyl-KTSAVLQSGFRKM-Glu(Edans)-NH2 is a fluorogenic peptide, as the substrate to measure the enzymatic activities of protease forms. Dabcyl-KTSAVLQSGFRKM-Glu(Edans)-NH2 can be used for researching 2019-nCoV (COVID-19) infection.

Garcinone B	Angiotensin-converting Enzyme (ACE) SARS-CoV	Infection
Garcinone B, a xanthone derivative, is a nature product that could be isolated from the pericarp of Mangosteen. Garcinone B is a potent ACE2 and Mpro inhibitor. Garcinone B can be used in research of COVID-19 .

Efmarodocokin alfa	Interleukin Related	Infection
Efmarodocokin alfa is a fusion protein of human IL-22 and the IgG4 crystallizable fragment. Efmarodocokin alfa activates IL-22 signaling. Efmarodocokin alfa can be used for the research of severe COVID-19 pneumonia .

Aranotin	SARS-CoV	Infection
Aranotin strongly binds to Nsp15 viral protein. Aranotin can be used as promising SARS-CoV-2 replication strong inhibitor. Aranotin has the potential for COVID-19 research .

SARS-CoV-2 Mpro-IN-14	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-14 (Compound 19) is an inhibitor of SARS-CoV-2 Mpro with an IC₅₀ of 0.044 μM. SARS-CoV-2 Mpro-IN-14 exhibits water solubility, has no cytotoxicity, and can be used in the study of COVID-19 .

Nezulcitinib TD-0903	JAK	Infection Inflammation/Immunology
Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation .

Siltuximab CNTO-328	Interleukin Related	Cancer
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .

Lenzilumab KB 003	SARS-CoV	Cancer
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .

SARS-CoV-2-IN-21	SARS-CoV	Infection
SARS-CoV-2-IN-21 (compound 10), a penicillin sulfone benzyl C6 derivative, is a potent SARS-CoV-2 main protease inhibitor, with an IC₅₀ of 5.3 μM. SARS-CoV-2-IN-21 can be used for COVID-19 research .

Daxdilimab MEDI7734; VIB7734	SARS-CoV	Cancer
Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research .

Burfiralimab hzVSF-v13	Interleukin Related SARS-CoV	Infection Inflammation/Immunology
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .

Regdanvimab CT-P59	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .

SARS-CoV-2-IN-46	SARS-CoV	Infection
SARS-CoV-2-IN-46 is a novel coronavirus (SARS-CoV-2) replication inhibitor with an EC₅₀ of 0.9 μM in Calu-3 cells. SARS-CoV-2-IN-46 has antiviral activity and can be used in novel coronavirus (COVID-19) research .

Sacubitril 1 Publications Verification AHU-377	Neprilysin	Infection Cardiovascular Disease
Sacubitril (AHU-377) is a potent and orally active NEP (neprilysin) inhibitor with an IC₅₀ of 5 nM. Sacubitril is a component of the heart failure medicine LCZ696. Sacubitril can be used for the research of heart failure, hypertension and COVID-19 .

Peramivir 5+ Cited Publications RWJ-270201; BCX-1812	IKK JNK STAT p38 MAPK ERK	Infection Inflammation/Immunology
Peramivir is an novel cyclopentane neuraminidase inhibitor of influenza virus. Peramivir has antiviral activity and anti-cytokines stom effects. Peramivir can be used for the research of COVID-19 .

TH1217 1 Publications Verification ZINC1775962367	SARS-CoV	Infection Cancer
TH1217 (ZINC1775962367) is a potent and selective dCTPase pyrophosphatase 1 (dCTPase) inhibitor, with an IC₅₀ of 47 nM. TH1217 enhances the cytotoxic effect of cytidine analogues in leukemia cells. TH1217 also could modulate SARS-Cov-2 interactors, so it shows activity of against COVID-19 .

SARS-CoV-2-IN-12	SARS-CoV	Infection
SARS-CoV-2-IN-12 (Compound 27) is a potent SARS-CoV-2-related 3C-like protease inhibitor (K_i=32.1 pM) for preventing SARS-CoV-2 viral replication and that could be useful in the research of COVID-19 .

SARS-CoV-2 nsp14-IN-4	SARS-CoV	Infection
SARS-CoV-2 nsp14-IN-4 (Compound 12q) is an inhibitor of SARS-CoV-2 nsp14 methyltransferase (IC₅₀=19 nM). SARS-CoV-2 nsp14-IN-4 is non-cytotoxic and cell-permeable. SARS-CoV-2 nsp14-IN-4 is used in COVID-19 research .

Dabcyl-KTSAVLQSGFRKME-Edans TFA 1 Publications Verification	SARS-CoV	Others
Dabcyl-KTSAVLQSGFRKME-Edans TFA is a fluorogenic peptide. Dabcyl-KTSAVLQSGFRKME-Edans TFA is used as the substrate to measure the enzymatic activities of protease forms. Dabcyl-KTSAVLQSGFRKME-Edans TFA has the potential for study 2019-nCoV (COVID-19) infection .

SARS-CoV-2-IN-32	SARS-CoV	Infection Cancer
SARS-CoV-2-IN-32 (compound 3g) is a COVID-19 inhibitor. SARS-CoV-2-IN-32 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-32 exhibits comparatively high binding affinity (-8.8 Kcal/mole) to COVID-19 main protease (M ^pro) (PDB ID: 6LU7). SARS-CoV-2-IN-32 can be used in studies of cancer and COVID-19 .

SARS-CoV-2-IN-33	SARS-CoV	Infection Cancer
SARS-CoV-2-IN-33 (compound 3m) is a COVID-19 inhibitor. SARS-CoV-2-IN-33 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-33 exhibits comparatively good binding affinity (-8.0 Kcal/mole) to COVID-19 main protease (M ^pro) (PDB ID: 6LU7). SARS-CoV-2-IN-33 can be used in studies of cancer and COVID-19 .

Imdevimab REGN10987	SARS-CoV	Infection
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .

Casirivimab REGN10933	SARS-CoV	Infection
Casirivimab (REGN10933) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Casirivimab lacks efficacy against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), it reduces viral load and improves diseases .

Coronastat NK01-63	SARS-CoV	Infection
Coronastat is a potent inhibitor of the SARS-CoV-2 3CL protease. The SARS-CoV-2 3CL protease is a critical agent target for small molecule COVID-19, given its likely agentgability and essentiality in the viral maturation and replication cycle .

CDK9-IN-25	CDK SARS-CoV Virus Protease	Infection
CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC₅₀: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC₅₀: 63.28 μM) .

Kazinol F	SARS-CoV	Infection Inflammation/Immunology
Kazinol F is a polyphenol from Broussonetia papyrifera. Kazinol F also is an effective Mpro inhibitor. Kazinol F has interaction with both the catalytic residues (His41 and Cys145) of Mpro and exhibits good binding affinity. Kazinol F can be used for the research of COVID-19 .

Chloroquine phosphate Maximum Cited Publications 529 Publications Verification	Parasite Autophagy SARS-CoV Toll-like Receptor (TLR) HIV Antibiotic	Infection Inflammation/Immunology Cancer
Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

Chloroquine Maximum Cited Publications 529 Publications Verification	Parasite Autophagy SARS-CoV Toll-like Receptor (TLR) HIV Antibiotic	Infection Inflammation/Immunology Cancer
Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

Cat. No.	Product Name

HY-L052

Anti-COVID-19 Compound Library

1477 compounds

COVID-19 poses a serious threat to people's health, and it is urgent to develop drugs to treat COVID-19 quickly. The screening of anti-COVID-19 drugs by using the clinical and approved compounds can greatly shorten the research and development cycle. In addition, the virtual screening technology can effectively narrow the scope of screening and improve the screening efficiency in the pre-screening of new drugs.

Taking advantage of our virtual screening, we conduct virtual screening of approved compound library and clinical compound library based on the 3CL protease (PDB ID: 6LU7), Spike Glycoprotein (PDB ID: 6VSB), NSP15 (PDB ID: 6VWW), RDRP, PLPro and ACE2 (Angiotensin Converting Enzyme 2) structure. We design a unique collection of 1477 compounds which may have anti-COVID-19 activity. Anti-COVID-19 Compound Library will be a powerful tool for screening new anti-COVID-19 activity drugs.

Cat. No.	Product Name	Type

HY-D1270

Direct Violet 1	Dyes
Direct Violet 1, an azo dye, is a textile dye. Direct Violet 1 is also the protein-protein interaction (PPI) between the SARS-CoV-2 spike protein and ACE2 inhibitor with IC₅₀s of 1.47-2.63 μM .

Cat. No.	Product Name	Type

HY-138170

ALC-0315 5+ Cited Publications	Drug Delivery
ALC-0315 is an ionisable aminolipid that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. ALC-0315 can be used to form lipid nanoparticle (LNP) delivery vehicles. Lipid-Nanoparticles have been used in the research of mRNA *COVID-19* vaccine .

HY-134541

SM-102 5+ Cited Publications	Drug Delivery
SM-102 is an amino cationic lipid useful in the formation of lipid nanoparticles (LNPs). SM-102 has higher transfection efficiency. SM-102 plays an important role in the effectiveness of lipid nanoparticles (LNPs) in delivering mRNA therapeutics and vaccines .

HY-153235

COVID-19 Spike Protein mRNA-LNP

Drug Delivery

COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing COVID-19 Spike Protein, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 Spike Protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 Spike Protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .

HY-153380

ALC-0315 analogue-2	Drug Delivery
ALC-0315 analogue-2 is an analogue of ALC-0315. ALC-0315 is an ionisable aminolipid that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. ALC-0315 can be used to form lipid nanoparticle (LNP) delivery vehicles. Lipid-Nanoparticles have been used in the research of mRNA COVID-19 vaccine.

Cat. No.	Product Name	Target	Research Area

HY-P2295

Dabcyl-KTSAVLQSGFRKME-Edans TFA 1 Publications Verification	SARS-CoV	Others
Dabcyl-KTSAVLQSGFRKME-Edans TFA is a fluorogenic peptide. Dabcyl-KTSAVLQSGFRKME-Edans TFA is used as the substrate to measure the enzymatic activities of protease forms. Dabcyl-KTSAVLQSGFRKME-Edans TFA has the potential for study 2019-nCoV (COVID-19) infection .

HY-16050

Plitidepsin 2 Publications Verification Aplidine; PM90001	DNA/RNA Synthesis SARS-CoV	Infection Cancer
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

HY-P3437

Dabcyl-KTSAVLQSGFRKM-Glu(Edans)-NH2	Virus Protease	Others
Dabcyl-KTSAVLQSGFRKM-Glu(Edans)-NH2 is a fluorogenic peptide, as the substrate to measure the enzymatic activities of protease forms. Dabcyl-KTSAVLQSGFRKM-Glu(Edans)-NH2 can be used for researching 2019-nCoV (COVID-19) infection.

HY-P2296

Abz-FRLKGGAPIKGV-EDDNP TFA	Fluorescent Dye	Others
Abz-FRLKGGAPIKGV-EDDNP TFA is a fluorogenic substrate used to measure the enzymatic activities of protease forms, such as papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV). Abz-FRLKGGAPIKGV-EDDNP TFA has the potential for study 2019-nCoV (COVID-19) infection .

HY-P1717

AMY-101 Cp40	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717B

AMY-101 acetate 2 Publications Verification Cp40 acetate	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717A

AMY-101 TFA 2 Publications Verification Cp40 TFA	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

Cat. No.	Product Name	Target	Research Area

HY-P99103

Bebtelovimab LY-3853113; LY-COV1404	SARS-CoV	Infection
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .

HY-P99810

Quisovalimab AVTX-002; AEVI 002; SAR 252067	SARS-CoV	Cardiovascular Disease
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .

HY-P99779

Plonmarlimab TJ003234; TJM2	c-Fms SARS-CoV	Infection Inflammation/Immunology
Plonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19 .

HY-145642

Masavibart ZRC3308-A7	SARS-CoV	Infection
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

HY-145643

Nepuvibart ZRC3308-B10	SARS-CoV	Infection
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

HY-P99919

Efmarodocokin alfa	Interleukin Related	Infection
Efmarodocokin alfa is a fusion protein of human IL-22 and the IgG4 crystallizable fragment. Efmarodocokin alfa activates IL-22 signaling. Efmarodocokin alfa can be used for the research of severe COVID-19 pneumonia .

HY-P9956

Siltuximab CNTO-328	Interleukin Related	Cancer
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .

HY-P99207

Lenzilumab KB 003	SARS-CoV	Cancer
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .

HY-P99226

Daxdilimab MEDI7734; VIB7734	SARS-CoV	Cancer
Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research .

HY-P99490

Burfiralimab hzVSF-v13	Interleukin Related SARS-CoV	Infection Inflammation/Immunology
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .

HY-P99346

Regdanvimab CT-P59	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .

HY-P99342

Imdevimab REGN10987	SARS-CoV	Infection
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .

HY-P99341

Casirivimab REGN10933	SARS-CoV	Infection
Casirivimab (REGN10933) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Casirivimab lacks efficacy against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), it reduces viral load and improves diseases .

HY-P99012

Clazakizumab	Interleukin Related SARS-CoV	Infection Inflammation/Immunology
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .

HY-P99520

Vilobelimab CaCP-29, IFX-1	Complement System SARS-CoV	Infection Inflammation/Immunology
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .

HY-P99642

Gimsilumab MORAb-022	c-Fms SARS-CoV	Infection Inflammation/Immunology
Gimsilumab (MORAb-022) is a human anti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA) .

HY-P99177

Enibarcimab	SARS-CoV	Infection Cardiovascular Disease
Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research .

HY-P99252

Itolizumab Anti-Human CD6 Recombinant Antibody	CD6	Infection Inflammation/Immunology
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .

HY-P99710

Lomtegovimab BI 767551; DZIF-10c	SARS-CoV	Infection
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .

HY-P9917

Tocilizumab 15+ Cited Publications Anti-Human IL6R, Humanized Antibody	Interleukin Related	Inflammation/Immunology Cancer
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .

HY-P99344

Bamlanivimab Anti-Human SARS-CoV-2	SARS-CoV	Infection
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .

HY-P99340

Sotrovimab VIR 7831	SARS-CoV	Infection
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .

HY-145644

Ogalvibart C-135-LS; BMS-986414	SARS-CoV	Infection
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .

HY-P99181

Mupadolimab CPI-006	CD73	Infection Inflammation/Immunology
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^POS B cells .

HY-P99450

Avdoralimab IPH 5401; Anti-C5aR1 mAb	Complement System	Inflammation/Immunology Cancer
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .

Species:	Virus (9)
Tag:	His (6) Tag Free (1) Avi (5) Fc (2)
Source:	HEK293 (4) Sf9 insect cells (3) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P78275

SARS-CoV-2 3CLpro/3C-like protease Protein

3C-like protease; 3CL Protease; 3CL-Mpro; 3CL Pro; COVID-19; M Proteinase; Mpro
Virus E. coli

HY-P78284

	SARS-COV-2 S Trimer Protein (D614G, HEK293, His-Avi) S protein; Spike glycoprotein; S glycoprotein; COVID-19	Virus	HEK293
	SARS-CoV-2 S1 Protein, in its Spike protein S1 form, initiates infection by attaching the virion to the cell membrane through host receptor interaction. Simultaneously, Spike protein S2' acts as a viral fusion peptide, revealing itself after S2 cleavage during virus endocytosis. SARS-COV-2 S Trimer Protein (D614G, HEK293, His-Avi) is the recombinant Virus-derived SARS-COV-2 S Trimer protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of SARS-COV-2 S Trimer Protein (D614G, HEK293, His-Avi) is 1173 a.a., with molecular weight of 175-230 kDa.

HY-P76591

SARS-CoV-2 3CLpro/3C-like protease Protein (sf9, His-Avi)

3CL Protease; 3CL Proteinase; 3C-like main protease; 3CL-Mpro; COVID-19; M Proteinase; Main Protease; Mpro
Virus Sf9 insect cells
HY-P76589

SARS-CoV-2 3CLpro/3C-like protease Protein (sf9, His)

3CL Protease; 3CL Proteinase; 3C-like main protease; 3CL-Mpro; COVID-19; M Proteinase; Main Protease; Mpro
Virus Sf9 insect cells
HY-P76590

SARS-CoV-2 3CLpro/3C-like protease Protein (His-Avi)

3CL Protease; 3CL Proteinase; 3C-like main protease; 3CL-Mpro; COVID-19; M Proteinase; Main Protease; Mpro
Virus E. coli

HY-P78106

	SARS-CoV-2 S Trimer Protein (Biotinylated, HEK293, His-Avi) S protein; Spike glycoprotein; S glycoprotein; COVID-19	Virus	HEK293
	SARS-CoV-2 S1 Protein, in its Spike protein S1 form, initiates infection by attaching the virion to the cell membrane through host receptor interaction. Simultaneously, Spike protein S2' acts as a viral fusion peptide, revealing itself after S2 cleavage during virus endocytosis. SARS-CoV-2 S Trimer Protein (Biotinylated, HEK293, His-Avi) is the recombinant Virus-derived SARS-CoV-2 S Trimer protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of SARS-CoV-2 S Trimer Protein (Biotinylated, HEK293, His-Avi) is 1173 a.a., with molecular weight of 140-170 kDa.

HY-P78286

	SARS-COV-2 S Trimer Protein (HEK293, His-Avi) S protein; Spike glycoprotein; S glycoprotein; COVID-19	Virus	HEK293
	SARS-CoV-2 S1 Protein, in its Spike protein S1 form, initiates infection by attaching the virion to the cell membrane through host receptor interaction. Simultaneously, Spike protein S2' acts as a viral fusion peptide, revealing itself after S2 cleavage during virus endocytosis. SARS-COV-2 S Trimer Protein (HEK293, His-Avi) is the recombinant Virus-derived SARS-COV-2 S Trimer protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of SARS-COV-2 S Trimer Protein (HEK293, His-Avi) is 1173 a.a., with molecular weight of 175-230 kDa.

HY-P73663

	SARS-CoV-2 S2 Protein (sf9, Fc) COVID-19; S2 protein; SARS-CoV-2 Spike; Spike glycoprotein Subunit 2; Spike protein S2	Virus	Sf9 insect cells
	The SARS-Cov-2 S glycoprotein is a SARS-Cov-2 S glycoprotein. The amino acid sequence 1261-1267a.a of the SARS-Cov-2 S glycoprotein is transmembrane. The SARS-Cov-2 S glycoprotein is a highly glycosylated trimer, each of which consists of 1260 amino acids (residues 14-1273), divided into four structural domains: the n-terminal domain (NTD), the c-terminal domain (CTD, also known as the receptor-binding domain, RBD), and two subdomains (SD1 and SD2). SARS-CoV-2 S2 Protein (sf9, Fc) is the recombinant Virus-derived SARS-CoV-2 S2 protein, expressed by Sf9 insect cells , with C-mFc labeled tag. The total length of SARS-CoV-2 S2 Protein (sf9, Fc) is 528 a.a., with molecular weight of ~84.33 kDa.

HY-P78282

	SARS-COV-2 S Trimer Protein (HEK293, Fc) S protein; Spike glycoprotein; S glycoprotein; COVID-19	Virus	HEK293
	SARS-CoV-2 S1 Protein, in its Spike protein S1 form, initiates infection by attaching the virion to the cell membrane through host receptor interaction. Simultaneously, Spike protein S2' acts as a viral fusion peptide, revealing itself after S2 cleavage during virus endocytosis. SARS-COV-2 S Trimer Protein (HEK293, Fc) is the recombinant Virus-derived SARS-COV-2 S Trimer protein, expressed by HEK293 , with C-hFc labeled tag. The total length of SARS-COV-2 S Trimer Protein (HEK293, Fc) is 1173 a.a., with molecular weight of 230-250 kDa.

Cat. No.	Product Name	Chemical Structure

HY-113225S2

Guanosine triphosphate-13C dilithium
Guanosine triphosphate- ¹³C (GTP- ¹³C) dilithium is ¹³C-labeled Guanosine triphosphate (HY-113225). Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19.

HY-113225S6

Guanosine triphosphate-d14 dilithium
Guanosine triphosphate-d₁₄ (GTP-d₁₄) dilithium is deuterium labeled Guanosine triphosphate (HY-113225). Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19.

HY-113225S3

Guanosine triphosphate-15N5 dilithium
Guanosine triphosphate- ¹⁵N₅ (GTP- ¹⁵N₅) dilithium is ¹⁵N labeled Guanosine triphosphate (HY-113225). Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19.

HY-113225S5

Guanosine triphosphate-13C10 dilithium
Guanosine triphosphate- ¹³C₁₀ (GTP- ¹³C₁₀) dilithium is ¹³C-labeled Guanosine triphosphate (HY-113225). Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19.

HY-113225S4

Guanosine triphosphate-15N5,d14 dilithium
Guanosine triphosphate- ¹⁵N₅,d₁₄ (GTP- ¹⁵N₅,d₁₄) dilithium is deuterium and ¹⁵N labeled Guanosine triphosphate (HY-113225). Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19.

HY-104077S

Remdesivir-d5 2 Publications Verification
Remdesivir-d₅ is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro[1][2].

HY-17589AS

Chloroquine-d5 1 Publications Verification
Chloroquine-d₅ is deuterium labeled Chloroquine. Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

HY-145119AS

Mindeudesivir hydrobromide
Mindeudesivir (JT001; VV116; GS-621763-d₁) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against *COVID-19, and is the first domestically produced deuterium targeting the COVID-19* .

HY-15407S3

Sacubitril-13C4
Sacubitril-13C4 (AHU-377-13C4) is a 13C-labeled version of Sacubitril (HY-15407). Sacubitril is an orally active inhibitor of neprilysin NEP (IC₅₀=5 nM). Sacubitril is used in research on heart failure, hypertension and COVID-19 .

HY-B0260S

Methylprednisolone-d3
Methylprednisolone-d₃ is the deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels[3].

HY-B0260S2

Methylprednisolone-d4
Methylprednisolone-d₄ is deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels[3].

HY-B0260S3

Methylprednisolone-d7
Methylprednisolone-d₇ is deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels[3].

HY-B0260S4

Methylprednisolone-d2
Methylprednisolone-d₂ is the deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels[3][4].

HY-17589S1

Chloroquine-d4 phosphate

Chloroquine-d₄ (phosphate) is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

HY-17589S

Chloroquine-d5 diphosphate

Chloroquine-d₅ (diphosphate) is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

HY-104077S1

Remdesivir-d4
Remdesivir-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-135853S

Molnupiravir-d7

Molnupiravir-d₇ is the deuterium labeled Molnupiravir. Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].

HY-104077S2

Remdesivir impurity 9-d4
Remdesivir impurity 9-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-14648S1

Dexamethasone-d5-1

Dexamethasone-d₅-1 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.

HY-14648S2

Dexamethasone-d4

Dexamethasone-d₄ is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.

HY-14648S

Dexamethasone-d5

Dexamethasone-d₅ is the deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses[1][2].

HY-B0402S1

Amantadine-d6

Amantadine-d₆ is the deuterium labeled Amantadine[1]. Amantadine (1-Adamantanamine) is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine also has anti-orthopoxvirus and anticancer activity. Amantadine can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research[2][3][4][5][6][7].

HY-14648S3

Dexamethasone-4,6α,21,21-d4

Dexamethasone-4,6α,21,21-d₄ is the deuterium labeled Dexamethasone-4,6α,21,21. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.

HY-14648S5

Dexamethasone-d3-1

Dexamethasone-d₃-1 (Hexadecadrol-d₃-1; Prednisolone F-d₃-1) is a deuterium labeled Dexamethasone (HY-14648). Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.

HY-113225S1

Guanosine triphosphate-13C10,15N5 tetraammonium
Guanosine triphosphate- ¹³C₁₀, ¹⁵N₅ (tetraammonium) is the ¹³C and ¹⁵N labeled Guanosine triphosphate tetraammonium[1]. Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19[2].

HY-B0180S

Imiquimod-d6
Imiquimod-d₆ is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

HY-B0180S1

Imiquimod-d9
Imiquimod-d₉ is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

HY-100442S

Paquinimod-d5
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-100442S1

Paquinimod-d5-1
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks